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ABSTRACT 
Whole exome sequencing is currently used for the diagnosis of genetic conditions in pediatric 
and adult patients. Prenatal genetic testing is commonplace, but clinical prenatal whole exome 
sequencing is currently not available by commercial laboratories. Controversy surrounds the 
ethical issues of knowing a fetus’s genetic future and the implications it could have for 
termination and family planning. While ongoing discussion occurs whether prenatal whole 
exome sequencing should be offered, there are no studies assessing parental opinions of prenatal 
whole exome sequencing. A questionnaire focusing on this was distributed to individuals that 
were pursuing first trimester genetic screening. The results of the questionnaire were analyzed 
using descriptive statistics. Results showed that 83.1% of participants thought prenatal whole 
exome sequencing should be offered and 53.5% (with an additional 40.1% neutral) were 
interested in having prenatal whole exome sequencing for their fetus. Only 17.2% of participants 
responded that they would be willing to have amniocentesis in order to have prenatal whole 
exome sequencing, and 30.6% were neutral towards amniocentesis. The vast majority of 
participants were interested in receiving all types of results, including: conditions of childhood 
and adult onset that are treatable, non-treatable, and that may shorten lifespan. In regards to 
family planning, 60.1% of participants stated the results of prenatal whole exome sequencing 
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may affect their family planning if they are at risk to have a future child with a health problem, 
and 32.8% (with 20.2% neutral) stated that results of prenatal whole exome sequencing may 
affect their decision to continue the pregnancy. The majority of participants (59.7%) preferred a 
maximum turnaround time of three weeks or less for prenatal whole exome sequencing which is 
much shorter than currently reported turnaround times. Although interest is expressed for 
prenatal whole exome sequencing, the current available technologies for fetal DNA capture and 
whole exome sequencing turnaround time is not desirable for expectant parents. The public 
health significance of this study is that prenatal whole exome sequencing will likely become 
clinically available as technologies continue to improve. Understanding the public’s views on the 
testing is important in order to predict uptake and any perceived barriers. 
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1.0  INTRODUCTION 
Whole exome sequencing (WES) is a type of genetic test that helps provide a diagnosis to 
individuals with a likely genetic condition. WES is able to simultaneously sequence the coding 
regions of the human genes and detect variation in a gene’s sequence.1,2 WES technology is 
particularly useful in diagnosis of rare genetic disorders, in which other genetic testing has failed to 
reveal a unifying diagnosis for a patient’s symptoms. With rare genetic conditions, single gene 
testing may not be available and WES becomes the best option to help determine a diagnosis. The 
diagnostic yield of WES has proved to be higher than other genetic testing options with on average 
25% of results revealing a clear diagnosis.3-6 WES is clinically offered to newborn, pediatric, and 
adult genetics patients. Prenatal WES is not currently available as a clinical test, but as technologies 
continue to improve it is likely that prenatal WES will become clinically available. The aim of this 
project was to analyze the responses given in a questionnaire regarding prenatal whole exome 
sequencing that was administered to expectant parents that were pursuing first trimester screening at 
Magee-Womens Hospital. The perceived interest in the testing was analyzed to help predict if there 
is interest in clinical prenatal WES and the implications it may have. 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 OVERVIEW 
2.1.1 Whole exome sequencing 
Whole exome sequencing (WES) is currently the most comprehensive clinical genetic testing 
available. WES is able to simultaneously sequence the coding regions of all known protein-coding 
genes (exome) in the human genome.1,7 The exome is estimated to comprise only 1% of the entire 
genome;2,7 however, it is thought that about 85% of disease causing mutations are found in the 
exome.2  
There are limitations of WES that must be considered when using WES as a clinical test. 
These limitations include: incomplete or low coverage of certain genes, lack of coverage of non-
coding regions that may have a functional element, and inability to detect copy number variants 
translocations, and inversions.1 Although there are several limitations to WES it still has many 
strengths. WES has an average diagnostic yield of 25%3-6 which is higher than other clinical genetic 
testing options.  
Some additional challenges arise with WES. Although cost of WES continues to decline it is 
still an expensive genetic test that is not always covered by health insurance plans.8,9 The informed 
consent process for clinical WES can be lengthy due to the numerous topics that must be covered in 
order for a patient to be able to make an informed decision about testing.10,11 Data handling is 
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another challenge due to shear amount of data that is generated by WES. It is estimated that 20,000 
variants will be revealed in any WES analysis.11 The issue of the returning of results of WES is 
another major challenge. There is much debate over which results should be returned as a part of a 
WES report. Mainly the debate focuses on the return of incidental findings and when they are 
appropriate to return.9 
Current technologies are using next generation sequencing (NGS) platforms to perform 
WES. NGS allows for sequencing of different DNA sequences in a single reaction.9 This allows for 
better coverage of the coding regions of the DNA and faster turnaround times.2 Previously, Sanger 
sequencing was used as a platform which relies on a “shotgun method” and thus resulted in a lower 
coverage of the exome.2  
2.1.2 Current prenatal genetic testing options 
In current clinical practice, there are several prenatal genetic screening and testing options. Genetic 
screening options that are available to all pregnant women include: first trimester screening 
(increased risk for aneuploidies such as trisomy 18 and trisomy 21), quad screen (increased risk for 
aneuploidies trisomy 18, trisomy 21, and spina bifida), or maternal serum AFP (increased risk for 
spina bifida). For pregnancies that are considered high risk (e.g. advanced maternal age, abnormal 
ultrasound finding, etc.), there are additional prenatal genetic testing options such as cell free DNA 
(increased risk for trisomy 13, trisomy 18, trisomy 21, and sex chromosome aneuploidies), and 
chorionic villi sampling or amniocentesis for karyotype, microarray, or single gene/single site 
testing for a known familial mutation.  
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2.2 PRENATAL WHOLE EXOME SEQUENCING  
2.2.1 The ACMG guidelines for whole exome sequencing 
The American College of Medical Genetics and Genomics (ACMG) has released several policy 
statements regarding WES. In 2012, the ACMG first published guidelines for when to consider 
clinical genomic sequencing. This policy statement discusses prenatal WES saying it should be 
considered when a fetus is likely to have a genetic disorder but other genetic tests have not been 
able to determine a diagnosis.7 This ACMG policy statement also recommends that WES should not 
be used for prenatal screening. In 2013, the ACMG published a list of a minimum of 57 genes 
which pathogenic or likely-pathogenic variants should be reported regardless of clinical indication 
for WES. This policy statement also declared that these incidental findings should be reported 
regardless the age of the patient.12,13 In 2015, the ACMG revised their policy on reporting on 
incidental (secondary) findings with WES. In this updated policy statement, the ACMG 
recommended that patients and parents of patients should be able to opt out of secondary analysis 
and reporting with WES.14 
An additional technical report was published by the ACMG in 2013, which focused on the 
ethical issues surrounding genetic testing of children. This report states that the ACMG does not 
support routine carrier testing for minors when there is no medical relevance for this testing. 
Additionally, this report supports the deferment of predictive testing of adult-onset conditions until 
adulthood, unless it is in the child’s best medical interest to have the testing in childhood or 
adolescence.15 WES may go against the suggestions of this ACMG technical report because 
information regarding a child’s carrier status of certain conditions or a predisposition to an adult-
onset condition as part of the primary or secondary findings. With WES in the prenatal settings, 
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individuals could use these findings to make reproductive decisions and could have more 
psychosocial implications than pediatric WES testing.  
2.2.2 Ethical debate of prenatal whole exome sequencing 
While the majority of debate for clinical WES surrounds the reporting of incidental (secondary) 
findings, additional ethical considerations must be taken into account for prenatal WES. One 
concern is that prenatal WES may violate the child’s future right to not know their genetic 
information once born. While the goal of prenatal WES would be to help the parents make informed 
reproductive decisions, in reality it may create more confusion or anxiety. Prenatal WES would 
almost certainly reveal some variants of unknown significance which may complicate the decision 
making process. There are concerns that the results of prenatal WES would lead to an increased 
number of pregnancy terminations based on increased risk of the child to develop a condition at 
some point in their life or based on uncertain results.16 
Another issues with prenatal WES is that the inclusion of incidental (secondary) findings 
with results may cross the line of diagnostic testing to a screening test.17 With many of the reported 
genes with WES incidental (secondary) findings being related to adult-onset conditions, some have 
argued that those results seem more like screening for a risk for future disease than preforming a 
diagnostic test. Furthermore, there is concern for the psychosocial burden information about non-
treatable or adult-onset conditions would create for the parents. There is also concern for 
stigmatization or discrimination of children that are born after the parents opted for prenatal WES 
and the result revealed a non-treatable condition or increased risk for an adult-onset condition.17 
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2.3  PROFESSIONAL OPINIONS OF WHOLE EXOME SEQUENCING 
There have been several studies that assessed genetic professionals’ views and experiences with 
genome sequencing. One study by Machini, et al. compared genetics professionals that have offered 
WES or whole genome sequencing (WGS) to professionals that have not yet offered WES/WGS. 
For the participants that stated they had not offered WES/WGS to patients, the main reasons for not 
offering the testing included: area of practice (e.g. prenatal), clinical utility, cost, interpretation 
challenges, insurance coverage, lack of guidelines, clinic or individual not ready to offer the testing, 
and novelty of the test. The genetics professionals that have offered WES/WGS to patients stated 
that challenges of the test included: insurance coverage/preauthorization, lack of training in result 
interpretation (e.g. variants of unknown significance), and the complexity of the informed consent 
process.18 Another study by Nardini, et al. focused on views of genetic counselors of WES/WGS in 
the newborn period especially in regard to using this technology for newborn screening. The 
majority of participants in this study stated they did not feel prepared to counsel for WES/WGS 
results for newborn screening.19 Some of the issues the genetic counselors that were surveyed for 
this study mentioned included: appropriateness of using WES/WGS as part of newborn screening, 
return of results and incidental (secondary) findings, and issues with the informed consent process.19 
In regards to the return of incidental results of WES, a study by Yu, et al. the majority of 
genetics professionals (85%) thought that incidental findings should be offered to adult patients and 
74% thought that incidental findings should offered to parents of a child that is having WES.20 In 
this same study, 68% of genetics professionals thought results of the ACMG minimum gene list 
should be returned to individuals pursuing WES regardless of indication.  A majority of participants 
thought that patient preference should be taken into account when considering which incidental 
findings to disclose.20 In a second study by Grove, et al. the majority of genetics professionals 
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thought that patient autonomy and values should be the main determinant in deciding which results 
to return.21   
2.4 PUBLIC OPINIONS OF WHOLE EXOME SEQUENCING 
2.4.1 Opinions of WES in adult setting 
There are two studies by Yu, et al. that surveyed individuals’ opinions on WES/WGS and the return 
of results from these types of genetic testing. From these studies, approximately 70% of participants 
expressed interest in participating in a WGS study. Approximately, 25% of participants stated they 
would want all results from WGS and about 75% of participants said they would want at least one 
genetic result reported to them ranging from results for increased risk for common conditions such 
as cancer or Alzheimer’s disease to conditions in which the person had a family history. A little less 
than 40% of participants indicated that there was at least one type of result they would not want to 
receive if tested. Many participants were interested in genetic testing results that are actionable, (i.e. 
has medical treatment or disease prevention). Some participants also indicated concerns for health 
and long-term care insurance that could limit their ability to follow-up if results revealed an 
increased risk to develop certain conditions.22,23  
2.4.2 Opinions of WES in pediatric setting 
A study by Sapp, et al. interviewed parents of children with rare genetic conditions to better 
understand the parents’ preferences for the return of results with WES. The participants were 
enrolled into an exome sequencing study through the National Institute of Health and as part of the 
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consent agreed to receive any life-saving results of exome sequencing. The parents were able to opt 
to learn about any variants that were possibly related to their child’s phenotype and variants that 
were related to human disease but not necessarily related to their child’s phenotype. All participants 
in this study expressed interest in receiving WES incidental (or secondary) finding results for 
conditions that were treatable or preventable in childhood. The majority of participants’ rationale 
for wanting these results was to be able to better guide their child’s healthcare. About half of 
participants indicated at least some interest in receiving secondary results regarding non-treatable or 
unpreventable conditions in childhood (e.g. adult-onset conditions). Approximately three-quarters 
of the participants were also at least somewhat interested in receiving carrier status information for 
their children.24 In two studies by Yu, et al., participants were less likely to be interested in having 
their child participate (about 50%) in a WGS study than their own participation (about 70%).22,23  
2.4.3 Opinions of WES in newborn setting 
Waisbren, et al. surveyed postpartum parents in the newborn unit to assess hypothetical interest in 
WES/WGS of their newborn. In this study, the majority of parents (82.7%) were at least somewhat 
interested in WES/WGS for their newborn. Individuals that reported a health concern for their 
newborn were less likely to express interest in WES/WGS than individuals whose newborn was 
reportedly healthy. Married couples were also somewhat less interested in WES/WGS for their 
newborn.25 
Bombard, et al. analyzed public views on using WES/WGS for newborn screening. This 
study showed that a majority of the participants (79.6%) would participate in newborn screening if 
WES/WGS were used which was somewhat less than participants (94.4%) that stated they would 
participate in newborn screening with the current technologies.26  
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3.0  MATERIALS AND METHODS 
3.1 SPECIFIC AIMS 
Aim 1: To assess parental attitudes towards prenatal WES and their desire for the testing. 
 
Aim 2: To analyze the results of the questionnaire to better understand parental preferences for 
return of results of prenatal WES. 
 
Aim 3: To understand the impact on family planning and psychosocial effect prenatal WES may 
have if offered clinically.   
3.2 QUESTIONNAIRE DESIGN 
The study questionnaire design was a new design but used questionnaires previously reported in 
literature on whole exome sequencing as a reference.26-28 The questionnaire first had a description 
of whole exome sequencing. This description included information on what WES is, when it is 
used, and what are the potential results or finding of WES. The questionnaire included questions to 
gauge parental receptiveness to prenatal WES, their willingness to undergo the necessary 
procedures in order to have prenatal WES, the types of results they would like to receive from 
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prenatal WES, and the impact the results would have on their family planning. The questionnaire 
also included questions regarding demographic information. The questionnaire was designed to be 
anonymous in nature, with no questions revealing identifying information. The questionnaire was 
assessed by a medical geneticist (Aleksandar Rajkovic), an obstetrician/gynecologist (Devereux N. 
Saller), a bioethicist (Lisa S. Parker), a pediatric genetic counselor who specializes in WES, and 
several prenatal genetic counselors from Magee-Womens Hospital for readability and relevancy of 
each question.  The study and questionnaire were approved as an exempt study by the Institutional 
Review Board of the University of Pittsburgh (PRO#14050637). 
3.3 QUESTIONNAIRE DISTRIBUTION  
Questionnaires were distributed to expectant parents pursuing first trimester screening from June 
2014 until October 2014. The prenatal genetic counselor that was on call each day at Magee-
Womens Hospital would attach the questionnaire to the flow sheet of each woman pursuing first 
trimester screening. The flow sheet is used during the check-in process so the questionnaire was 
distributed to individuals pursuing first trimester screening by the staff at the front desk of the 
genetics ultrasound waiting area at Magee-Womens Hospital at the time of check-in. These 
individuals were also given a cover letter that explained the study and that it was voluntary to 
participate. Please see Appendix A for the cover letter and questionnaire. When the questionnaires 
were completed they were returned to the staff at the front desk or to an ultrasound tech. The 
questionnaires were kept in a confidential location until a genetic counselor collected them and 
returned them to the study team.  
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3.4 ANALYSIS OF RESULTS 
Descriptive analysis was performed for all questions of the survey. Non-responders were not 
included in the analysis of each question with the exception of the demographic information.  
Special consideration had to be taken into account for two questionnaires. A total of 184 
questionnaires were returned and were at least partially completed. Two of the 184 questionnaires 
were completed by both the male and female partner on a single copy of the questionnaire instead of 
completing separate questionnaires. Both partners answered the questionnaires with the same 
answers to each question except for the following demographic information: gender, age, and 
education level. For the purpose of analysis, these questionnaires were counted twice (once for the 
male and once for the female) making the total number of questionnaires 186. An additional special 
consideration that had to be taken into account was for the question regarding the preferred 
individual to return the results of prenatal WES, which was supposed to be answered with one 
choice. Twenty-six participants misunderstood this question to be a select all that applied. For the 
analysis, this question was analyzed as a select all that applied and counted each selected answer 
individually. 
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4.0  RESULTS 
Table 1 shown below describes the demographic information of the 186 participants in the study. 
The overall response rate of the questionnaire was 23.0% (186/808). Refer to Appendix A for a 
copy of the questionnaire. Of the 186 respondents, the sample was predominantly female (90.9%), 
white (70.4%), and college-educated (57% had Bachelor’s degree or greater). The median age the 
participants was 29 years old.  Of all participants, 33.9% reported that this was their first pregnancy, 
18.3% reported having prior genetic counseling, and 16.7% reported a family history of congenital 
anomaly or genetic condition. 
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Table 1. Demographic Summary of Participants 
 Total (n=186) 
 n % 
Sex      
     Female 169 90.9 
     Male 5 2.7 
     Did Not Answer 12 6.5 
Age   
     <20 9 4.8 
     20-29 80 43.0 
     30-39 82 44.1 
     40+ 3 1.6 
     Did Not Answer 12 6.5 
Race   
     White 131 70.4 
     Black 25 13.4 
     Asian 10 5.4 
     Other 6 3.2 
     Did Not Answer 14 7.5 
Education   
     Less than High School Diploma 4 2.3 
     High School Diploma/GED 32 17.2 
     Some College 34 18.2 
     Bachelor’s Degree 38 20.4 
     Some Graduate Level 10 5.4 
     Graduate Degree or Beyond 58 31.2 
     Did Not Answer 10 5.4 
First Pregnancy   
     Yes 63 33.9 
     No 113 60.8 
     Did Not Answer 10 5.4 
Prior Genetic Counseling   
     Yes 34 18.3 
     No 140 75.3 
     Did Not Answer 12 6.5 
Family/Pregnancy History of Congenital Anomaly   
     Yes 31 16.7 
      No 146 78.5 
     Did Not Answer 9 4.8 
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Table 2 describes the expectant parents’ desire to have prenatal WES and the willingness to 
undergo necessary procedures in order to have prenatal WES. If participants did not respond to the 
question, the non-response was not included in the analysis of that particular question. The number 
of responses for each question is listed in the table. 
 Most responders (83.1%) agreed that prenatal WES should be offered, 14.8% of participants 
were neutral to this notion, and while 2.2% were opposed to prenatal WES. About half (53.3%) 
indicated that they would want prenatal WES for their fetus with an additional 40.1% of participants 
expressing a neutral feeling of having prenatal WES for their fetus. A significant minority (34.6%) 
of participants expressed the desire for prenatal WES even if there was no indication of a medical 
problem and 30.2% were neutral that they would want WES in the absence of a medical indication. 
Only 17.2% of participants reported willingness to have an invasive procedure, such as 
amniocentesis, for prenatal WES, with an additional 30.6% of participant expressed a neutral 
attitude toward this notion. Over half (52.2%) of participants expressed unwillingness to have 
amniocentesis in order to have prenatal WES. There was a significant minority (44.2%) of 
participants who agreed they would want prenatal WES only if amniocentesis was not required and 
30.6% of participants expressed a neutral opinion towards desiring prenatal WES only if 
amniocentesis was not required. Only 16.6% of participants disagreed that they would want prenatal 
WES only if amniocentesis was not required.   
 
 
 
 
 
 
 
  15 
Table 2. Parental desire and willingness to have prenatal whole exome sequencing (WES) 
 Number of 
Responders 
Agree  Neutral Disagree  
If my baby is born with a birth defect or medical 
problem, I want to know the cause.  
 
183 170 
(92.9%) 
10  
(5.5%) 
3  
(1.6%) 
If my baby has a birth defect or medical problem, I 
would do any available genetic test to help determine a 
possible cause.  
183 126 
(68.9%) 
48  
(26.2%) 
9  
(4.9%) 
If my baby has a birth defect or medical problem, it is 
important for me to know the cause while the baby is in 
the womb.  
183 101 
(55.2%) 
60 
(32.8%) 
22  
(12.0%) 
WES should be offered to pregnant women for their 
baby if there is a problem identified by ultrasound or 
other means.  
183 152 
(83.1%) 
27 
(14.8%) 
4  
(2.2%) 
I would want my baby to have WES while in the womb 
if it was available. 
 
182 97 
(53.3%) 
73 
(40.1%) 
12  
(6.6%) 
Even if my baby has no indication of a birth defect or 
genetic condition, I would want my baby to have WES 
while in the womb to learn about his/her other genetic 
risks.  
182 63 
(34.6%) 
55 
(30.2%) 
64  
(35.2%) 
I would have amniocentesis in order to have WES for 
my baby.  
 
180 31 
(17.2%) 
55 
(30.6%) 
94  
(52.2%) 
I would want to have WES for my baby while in the 
womb only if I did not have to have amniocentesis.  
 
181 80 
(44.2%) 
71 
(39.2%) 
30  
(16.6%) 
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Table 3 shown below summarizes the participants’ opinions for the return of results of prenatal 
WES. Table 3 in particular focuses on the types of incidental (secondary) findings the expectant 
parents would want to receive as part of prenatal WES. Only 9.3% of participants stated they would 
want prenatal WES only if incidental findings were not reported and 22.5% of participants indicated 
they would want prenatal WES only if they could choose which incidental are reported to them. The 
vast majority of participants agreed that they would want to know about both treatable childhood 
conditions (96.2%) and non-treatable childhood conditions (86.3%). Most participants also agreed 
for treatable adult-onset (76.0%) and non-treatable adult-onset conditions (74.3%).  However, 
70.2% reported that an increased risk for adult-onset conditions would cause them anxiety and 
71.4% reported that a variant of unknown significance would cause them anxiety. Participants 
indicated that WES findings could influence future family planning, with 60.1% of participants 
agreeing it would influence it, 26% expressing neutral feelings, and only 14% disagreeing that WES 
results would influence family planning. In regards to reproductive decisions, 32.8% indicated that 
results of prenatal WES may affect their decision to continue the pregnancy and 47.0% of 
participants disagree that results of prenatal WES would affect their decision to continue the 
pregnancy.  
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Table 3.  Parental opinions regarding results of whole exome sequencing (WES) 
 Number of 
Responders 
Agree Neutral Disagree 
 
I would want my baby to have WES while in the womb 
only if any incidental findings are not reported. 
  
183 17 
(9.3%) 
82 
(44.8%) 
84 
(45.9%) 
I would want my baby to have WES while in the womb 
only if I can choose which incidental findings are 
reported to me.  
182 41 
(22.5%) 
65 
(35.7%) 
76 
(41.8%) 
I would want to know if my baby has a childhood onset 
disorder that could be treated before symptoms occur. 
 
182 175 
(96.2%) 
7  
(3.8%) 
20 
(11.0%) 
I would want to know if my baby has a childhood onset 
disorder that has no treatment or cure. 
 
182 157 
(86.3%) 
17 
(9.3%) 
8 
(4.4%) 
I would want to know if my baby had an increased risk 
for a disorder that could not be treated until adulthood. 
 
183 139 
(76.0%) 
27 
(14.8%) 
17  
(9.3%) 
I would want to know if my baby has an increased risk 
for disorder of adulthood that has no treatment or cure. 
183 136 
(74.3%) 
26 
(14.2%) 
21 
(11.5%) 
Finding out my baby is at an increased risk for a 
disorder of adulthood would cause me anxiety. 
 
181 127 
(70.2%) 
41 
(22.7%) 
13  
(7.2%) 
It would cause me anxiety if my baby had a “variant of 
unknown significance” as part of his/her WES results. 
 
182 130 
(71.4%) 
34 
(18.9%) 
18  
(9.9%) 
WES may reveal that the pregnancy has a different 
father than expected (non-paternity). I would want that 
result reported.  
177 119 
(67.2%) 
45 
(25.4%) 
13  
(7.3%) 
The results of WES would affect my decision about 
having more children in the future if the results show I 
am at risk to have other children with health problems. 
178 107 
(60.1%) 
46 
(25.8%) 
25 
(14.0%) 
If my baby has a birth defect or medical problem, 
knowing the cause may affect my decision to continue 
the pregnancy. 
183 60 
(32.8%) 
37 
(20.2%) 
86 
(47.0%) 
A patient should discuss the possible results of whole 
exome sequencing with a medical professional before 
having the test. 
177 171 
(96.6%) 
5 
(2.8%) 
1 
(0.6%) 
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Figure 1 and figure 2 depict the parental desire for the types of childhood onset conditions they 
would want to be reported with prenatal WES. Figure 1 shows the total percentage of responders 
that would want various types of childhood onset conditions reported. The majority of participants 
stated they would want results regarding conditions of childhood that are treatable (91.8%), non-
treatable (81.4%), and conditions that may shorten lifespan (82.5%).  
 
 
Figure 1. Types of results participants would want to be reported with prenatal whole exome sequencing 
regarding childhood onset conditions (n=183). 
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Figure 2 describes the combinations of types of childhood onset conditions expectant parents would 
want to be reported with prenatal WES. The majority of participants (76.5%) indicated that they 
would want to know about all types of results for childhood conditions (treatable conditions, non-
treatable condition, and conditions that shorten lifespan). Only 4.4% of participants stated that they 
would not want any results relating to childhood onset conditions reported to them. 
Figure 2. Types of childhood onset conditions participants would want to be reported with prenatal whole 
exome sequencing (n=183). 
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Figure 3 and figure 4 depict the parental desire for the types of adult onset conditions they would 
want to be reported with prenatal WES. Figure 3 shows the total percentage of responders that 
would want various types of adult onset conditions reported. The majority of participants stated they 
would want results regarding adult onset conditions that are treatable (86.8%), non-treatable 
(76.9%), and conditions that may shorten lifespan (79.1%). 
 
 
Figure 3. Types of results participants would want to be reported with prenatal whole exome sequencing 
regarding adult onset conditions (n=182). 
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Figure 4 describes the combinations of types of adult onset conditions expectant parents would 
want to be reported with prenatal WES. The majority of participants (72.5%) indicated that they 
would want to know about all types of results for childhood conditions (treatable conditions, non-
treatable condition, and conditions that shorten lifespan). Only 8.8% of participants stated that they 
would not want any results relating to childhood onset conditions reported to them. 
 
 
Figure 4. Types of adult onset conditions participants would want to be reported with prenatal whole exome 
sequencing (n=182). 
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Figure 5 describes how participants responded to the question “How much did you know about 
whole exome sequencing before this study?” Over 75% of participants indicated that they did not 
know what WES was prior to this questionnaire. A total of 24% of participants expressed that they 
at least know WES was a type of genetic testing. There was one person that responded “Other” and 
commented that they were not sure if this was the type of testing their doctor had talked to them 
about.  
 
Figure 5. Prior knowledge of participants on whole exome sequencing (n=179). 
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Figure 6 describes the participants preferred turnaround time for prenatal WES. More than half of 
participants expressed preference for a turnaround time from the collection of sample to the 
reporting of results of less than 3 weeks (with 11.7% preferring <1 week and an additional 48.0% 
referring 1-3 weeks). 
 
 
Figure 6. Parental preferences for whole exome sequencing (WES) turnaround time (n=179). 
 
 
 
 
 
 
 
 
  24 
Figure 7 describes the participants preferred professional to return results of prenatal WES. The 
majority of participants expressed a desire to receive WES results from a genetics professional 
(62.0%). Many participants were also willing to receive results from their OB/GYN (48.6%).  Few 
participants indicated a desire to receive prenatal WES results from their primary care provider 
(5.6%) or pediatrician (6.1%).  
 
 
Figure 7. Parental preferences for individual to return whole exome sequencing (WES) results (n=179). 
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5.0  DISCUSSION 
5.1 ANALYSIS OF QUESTIONNAIRE 
The data from Table 2 showed that a majority of participants (83.1%) felt that prenatal WES should 
be offered. Additionally, over half of participants (53.3%) expressed that they would want to have 
prenatal WES for their fetus with an additional 40.1% that were neutral towards prenatal WES. A 
significant minority of participants (34.6%) thought prenatal WES should be offered even if there 
was no medical indication identified. There was much interest expressed in prenatal WES by the 
participants. Several participants commented on their personal desire for prenatal WES stating, “I 
want to be able to have any test needed for me to have a healthy pregnancy,” and “Better to know 
than not to know.” One participant who was educated on WES stated, “I read a few journal articles 
about whole exome sequencing and wish it were available to me and covered by insurance. Another 
important reason to do whole exome sequencing would be to contribute to research on risk for 
identified variants (conditions that may develop from them) to better identify environmental 
(biopsychosocial) risk for developing a condition.” 
Although, there was interest in prenatal WES, the participants knew little about WES prior 
to this study, with 75.3% of participants having never heard of it or did not know what it. This must 
be taken into consideration when assessing hypothetical interest and actual uptake of the testing if 
offered. When individuals are better explained the testing, types of results, implications the results 
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may have on future medical management, and psychosocial implications, they may have differing 
attitudes regarding prenatal WES than were expressed in this questionnaire.   
Other factors that may affect hypothetical interest in prenatal WES versus actual uptake are 
the current turnaround time for WES and the need for an invasive procedure, such as amniocentesis, 
in order to have prenatal WES. The majority of participants (59.7%) stated that the preferred 
turnaround time for prenatal WES results is three weeks or less. This is much shorter than the 
current advertised turnaround time of 8 – 15 weeks by various testing laboratories.29-31 Current 
WES technologies would require an invasive procedure, such as chorionic villi sampling or 
amniocentesis, in order to be able to perform prenatal WES. A little less than half of participants 
(44.2%) stated that they would want prenatal WES only if amniocentesis did not have to be 
performed. A non-invasive option for prenatal WES may be preferred over an invasive procedure. 
A couple of participants even commented on their concerns of the safety of the test. One participant 
wrote, “Is it safe for me and the baby where I would not miscarry?” Another participant 
commented, “I would be for the sequencing if it was of little to no risk to the baby.” 
Incidental (secondary) findings of WES continue to be center of debate among 
professionals. There has been much discussion over which type of incidental findings should be 
reported with WES and if individuals should be able to opt-out of receiving any of these findings. 
Participants in this study had strong interest in receiving all types of incidental (secondary) findings, 
with the majority of participants wanting to know about childhood onset and adult-onset conditions 
that are treatable, non-treatable, or may shorten lifespan even though over 70% of participants 
stated that finding out their fetus was at an increased risk for an adult onset condition would cause 
them anxiety. Additionally, 71.4% of participants agreed that a variant of unknown significance 
would cause them anxiety, but participants still had a desire to receive all results of prenatal WES. 
One participant commented on the anxiety that may be created through prenatal WES commenting, 
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“I’d be happy to get testing done if it was definitive, not if there is a chance of a disorder and if 
there were false positives. Only 100% definitive results. I don’t want to know about adulthood. That 
would cause great anxiety for decades down the road although this sounds like a great idea initially 
it makes me wonder if it is going against nature or ethics by looking into the genetics that much. I 
found myself very torn.” 
In terms of reproductive and family planning, the opinions of the expectant parents were 
somewhat more divided. When asked if knowing the cause of a health problem in the fetus would 
affect their decision to continue the pregnancy, 32.8% of participants agreed and 20.2% were 
neutral. Furthermore, 60.1% of participants expressed that if prenatal WES results indicated that 
they were at risk to have a future child with health problems it would affect their decision to have 
more children. One participant even commented on the concern for how prenatal WES may affect 
reproductive decisions stating, “I understand the usefulness of genetic testing but there should be a 
limit. We don’t need to know everything before it happens. I fear the amount of abortions that 
would occur due to ‘risk’ for certain conditions.” 
5.2 LIMITATIONS OF STUDY AND FUTURE DIRECTIONS 
There were several limitations to this study. The response rate of the study was 23.0% (186/808). 
Due to the nature of this anonymous study, it is impossible to know if there was a significant 
difference between responders and non-responders. Comparing the study population’s 
demographics to the demographics of Allegheny County32, there were some obvious differences. 
According to Allegheny County census data from 2008-2012, 35.1% of residents age 25 or older 
have a Bachelor’s degree or higher compared to the study population which 57% of individuals had 
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at least a Bachelor’s degree. The higher rate of college educated individuals that participated in the 
study may have introduced some bias in that they were more likely to participate in the research 
study and the results are not reflective of the general population’s opinions, but it is difficult to 
predict if this is a meaningful comparison because the Allegheny County data includes individuals 
that are older than child bearing years and may have been less likely to pursue a higher degree. 
Census data from 2013, 51.9% of residents of Allegheny County are female which is much lower 
than the 91.0% of female participants in the study population. When considering the lack of male 
participation (2.7%), it can be hypothesized that male participation was low due to disinterest in 
participating in research, lack of involvement in the appointment, or were unaware of the study. 
Racial background of participants in the study was similar to Allegheny County. Racial summary of 
the study cohort compared to Allegheny County are as follows: white- 70.4% versus 79.9%, black- 
13.4% versus 13.3%, Asian- 5.4% versus 3.2%, and all other races- 3.2% versus 3.2%. In the study 
cohort, 7.5% of participants did not respond to this question so the actual racial summary may be 
different than what was reported. 
Another limitation to this study was the limited amount of information provided to the 
participants about WES before having them form an opinion. As a whole, the study cohort was 
rather uneducated on prenatal WES. If individuals were better educated on the subject matter they 
may have different opinions than what they expressed in the study. One study participant even 
noted her confusion on the study subject stating, “I understand some of these questions but still a 
little confused by a lot of it.” 
Future directions of this study would be to expand the study population in several ways. 
First, it would be important to have more expectant fathers participate in order to eliminate any bias 
that may arise from having a majority of women participants. Additionally, the study could be 
expanded to include expectant parents from varying gestational ages, and varying levels of testing, 
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such as no prenatal testing or screening, first trimester screen, non-invasive prenatal testing, and 
chromosome analysis through amniocentesis or chorionic villi sampling. The study would also 
benefit by giving participants a more detailed description of WES and explaining in detail ethical 
questions surrounding prenatal WES with a longer time frame for reflection on the issue. This 
would help to assess if parental opinions of prenatal WES change as they become more informed on 
the subject. 
5.3 PUBLIC HEALTH SIGNIFICANCE 
Currently, commercial genetic testing laboratories do not offer prenatal WES even though the 
ACMG guidelines state that WES may be considered if the fetus likely has a genetic condition. 
These guidelines also state that WES should not be used as a prenatal screening method.7 As the 
WES testing technology improves and more in known about the human genes and genome, it is 
inevitable that prenatal WES will be offered more readily to the public. Knowing if there is interest 
from the public in this type genetic testing is important before making it available as it require many 
valuable resources that could otherwise be used elsewhere.  
Over time prenatal WES may become more available as a prenatal genetic testing option. As 
this study showed, the majority of participants did not know anything about WES prior to the 
questionnaire. In order for WES to be a prenatal testing option, public education should take place 
so that there is a better understanding of the test before it is performed.  
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5.4 CONCLUSIONS 
Parental opinions regarding prenatal WES was studied, specifically in regards to desire for testing,  
willingness to have necessary procedures in order to have prenatal WES, types of results parents 
would want reported, and implications results may have on psychosocial effect and family planning. 
Demographic information was collected to help determine if bias was introduced into the study. The 
answers to the study questionnaire were analyzed using descriptive summaries. The majority of 
participants thought that prenatal WES should be offered and a little over half of the participants 
stated that they would want the test if available. The majority of participants were also interested in 
receiving all types of results even though the results may provoke anxiety.  
These results are helpful to predict the uptake of prenatal WES by expectant parents if made 
clinically available. While there is interest from expectant parents, the current technologies may not 
meet their expectations in regards to fetal DNA capture and turnaround times for results. 
Additionally, some concerns were expressed on how this testing may affect reproductive decisions 
and the psychological burden it may create by knowing so much genetic information before a child 
is even born. 
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APPENDIX A: PRENATAL WHOLE EXOME SEQUENCING QUESTIONNAIRE 
A.1 COVER LETTER 
Study Title: Understanding Parental Opinions on Whole Exome Sequencing in the Prenatal Setting 
 
The purpose of this questionnaire is to assess parent’s feelings on whole exome sequencing 
performed on babies while still in the womb. For this reason, we will be surveying pregnant women 
and their partner at Magee-Womens Hospital and ask them to complete a brief (approximately 15 
minutes) questionnaire. All participants of this research study must be 18 years or older in age. If 
you are willing to participate, the questionnaire will ask you about background (e.g. gender, race, 
age, education, pregnancy history), as well as about your feelings on whole exome sequencing 
performed on babies while still in the womb. This genetic technique is currently not offered for 
babies that are still in the womb. There are no anticipated risks associated with this study, nor any 
direct benefits to you. Please read the explanation of whole exome sequencing and complete the 
questionnaire. This questionnaire is entirely anonymous, your responses will be kept strictly 
confidential, and results will be kept under lock and key. Your participation is voluntary and you 
may choose to stop filling out the questionnaire after you have begun and not submit it. This study 
is being conducted by Eve Kalynchuk, who can be reached at kalynchuke2@mwri.magee.edu or 
412-641-7547, if you have any questions. Please complete this questionnaire only one time. When 
you complete your questionnaire, please return it to the sonographer or ultrasound tech. Thank you! 
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A.2 COMPREHENSIVE QUESTIONNAIRE 
WHAT IS WHOLE EXOME SEQUENCING? 
 
Whole exome sequencing is a new type of genetic test that has been shown to help find a genetic 
explanation for a patient’s medical problems. This test works by reading portions of a person’s 
DNA, which is in every cell of the body. The test looks for changes in the DNA sequence that are 
not detected by many of the other genetic techniques that are currently used. If there is a change in 
the DNA sequence, it could potentially cause health problems. Whole exome sequencing, in 
addition to finding disease causing changes, has been shown to identify other variations in the 
DNA. The following table describes the types of changes in the DNA sequence that can be reported 
from whole exome sequencing: 
 
Type of Results What it means 
Disease Causing Variant Change in a gene that causes disease or defect 
Benign Variant Change in a gene that does not cause disease or defect 
Variant of unknown significance Change in a gene that the effect is unknown at this time 
Incidental finding* Change in a gene that is associated with risk for developing 
a disease that may not be related to current condition 
 
*Example of an incidental finding: A baby may have whole exome sequencing in attempt to find the 
genetic cause for a birth defect, but it may discover that the baby has a change in the DNA sequence 
that can increase a person’s lifetime risk for breast cancer, ovarian cancer, and/or other types of 
cancer.  
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Based on the information above please answer the following questions. 
1. Whole exome sequencing may reveal something about your baby, which may also reveal 
information about your own health. For example, your baby may have a change in their DNA 
that causes a condition of adulthood and you could potentially have the same change in your 
DNA. Would this possibility influence your decision to have your baby tested using whole 
exome sequencing? [  ] Yes [  ] No   
 
2. There are several different types of incidental findings that could be reported from whole exome 
sequencing regarding increased risks for conditions that develop in childhood. What type of 
these findings would you want reported if your baby had whole exome sequencing? 
 Please select all that apply. 
  [  ] Treatable conditions   [  ] Conditions that may shorten lifespan 
  [  ] Non-treatable conditions   [  ] None 
 
3.  There are several different types of incidental findings that could be reported from whole exome 
sequencing regarding increased risks for conditions that develop in adulthood. What type of 
these findings would you want reported if your baby had whole exome sequencing? 
 Please select all that apply. 
  [  ] Treatable conditions   [  ] Conditions that may shorten lifespan 
  [  ] Non-treatable conditions   [  ] None 
 
4. If you chose to have whole exome sequencing while your baby is still in the womb, who should 
report the results to you? Please select one. 
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  [  ] OB/GYN (Obstetrician/gynecologist)  [  ] Pediatrician 
  [  ] Primary care physician    [  ] Other: ____________________________ 
  [  ] Genetics Professional 
 
5.  The length of time it takes to get results of genetic testing varies from a couple days to several 
weeks depending on the test. How long do you feel is an acceptable amount of time to wait for 
whole exome sequencing results for your baby while still in the womb? Please select one. 
 [  ] Less than 1 week    [  ] 7-10 weeks 
  [  ] 1-3 weeks     [  ] 10-15 weeks 
  [  ] 4-6 weeks     [  ] Over 15 weeks  
       [  ] It does not matter as long as it is before the baby is born
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Please circle one option for each of the following statements to best describe how you feel. 
1. If my baby is born with a birth defect or 
medical problem, I want to know the cause. 
 
 Agree Neutral Disagree 
2. If my baby has a birth defect or medical 
problem, I would do any available genetic 
test to help determine a possible cause. 
 
 Agree Neutral Disagree 
3. If my baby has a birth defect or medical 
problem, it is important for me to know the 
cause while the baby is in the womb. 
 
 Agree Neutral Disagree 
4. If my baby has a birth defect or medical 
problem, knowing the cause may affect my 
decision to continue the pregnancy. 
 
 Agree Neutral Disagree 
5. Whole exome sequencing should be offered 
to pregnant women for their baby if there is 
a problem identified by ultrasound or other 
means. 
 
 Agree Neutral Disagree 
6. I would want my baby to have whole exome 
sequencing while in the womb if it was 
 Agree Neutral Disagree 
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available. 
 
7. Even if my baby has no indication of a birth 
defect or genetic condition, I would want 
my baby to have whole exome sequencing 
while in the womb to learn about his/her 
other genetic risks. 
 Agree Neutral Disagree 
 
8. I would want my baby to have whole exome 
sequencing while in the womb only if any 
incidental findings are not reported. 
 
 Agree Neutral Disagree 
9. I would want my baby to have whole exome 
sequencing while in the womb only if I can 
choose which incidental findings are 
reported to me. 
 
 Agree Neutral Disagree 
10. I would have amniocentesis (a genetic 
testing procedure used to test babies still in 
the womb with a 1:1000 risk of miscarriage) 
in order to have whole exome sequencing 
for my baby. 
 
 Agree Neutral Disagree 
11. I would want to have whole exome  Agree Neutral Disagree 
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sequencing for my baby while in the womb 
only if I did not have to have amniocentesis. 
 
12. It would cause me anxiety if my baby had a 
“variant of unknown significance” as part of 
his/her whole exome sequencing results. 
 
 Agree Neutral Disagree 
13. Finding out my baby is at an increased risk 
for a disorder of adulthood would cause me 
anxiety. 
 
 Agree Neutral Disagree 
14. I would want to know if my baby had an 
increased risk for a disorder that could not 
be treated until adulthood. 
 
 Agree Neutral Disagree 
15. I would want to know if my baby has an 
increased risk for disorder of adulthood that 
has no treatment or cure. 
 
 Agree Neutral Disagree 
16. I would want to know if my baby has a 
childhood onset disorder that could be 
treated before symptoms occur. 
 Agree Neutral Disagree 
17. I would want to know if my baby has a  Agree Neutral Disagree 
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childhood onset disorder that has no 
treatment or cure. 
 
18. I would want to have whole exome 
sequencing on my baby if treatment for any 
identified problem was available for my 
baby while still in the womb. 
 
 Agree Neutral Disagree 
19. The results of whole exome sequencing 
would affect my decision about having more 
children in the future if the results show I 
am at risk to have other children with health 
problems. 
 
 Agree Neutral Disagree 
20. Whole exome sequencing may reveal that 
the pregnancy has a different father than 
expected (non-paternity). I would want that 
result reported. 
 
 Agree Neutral Disagree 
21. A patient should discuss the possible results 
of whole exome sequencing with a medical 
professional before having the test. 
 Agree Neutral Disagree 
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How much did you know about whole exome sequencing before this study? Please select one. 
 [  ] I never heard of it. 
 [  ] I heard of it, but did not know what it is. 
 [  ] I knew it is a type of genetic testing. 
 [  ] I knew it is a type of genetic testing and what the potential findings are. 
[  ] Other: ____________________________________________________ 
 
Additional Comments: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
DEMOGRAPHIC INFORMATION 
 
Gender: ______________________ 
Race: ________________________ 
Age: _________________________ 
Highest level of education completed: 
 [  ] Less than high school  [  ] Bachelor’s degree 
 [  ] High school/ GED   [  ] Some graduate level 
 [  ] Some college   [  ] Graduate degree or beyond 
How far along are you in your current pregnancy? ________ Weeks _______ Days  
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Is this your first pregnancy? [  ] Yes [  ] No 
Have you ever had genetic counseling? [  ] Yes [  ] No 
Has the baby of this pregnancy been diagnosed with a birth defect or medical problem?  
[  ] Yes [  ] No   If yes, please describe: ________________________________________ 
Have you ever had a pregnancy in which the baby had a birth defect or medical problem?  
[  ] Yes [  ] No   If yes, please describe: ________________________________________ 
Was anyone in your family born with a birth defect or genetic condition?  
[  ] Yes [  ] No   If yes, please describe: ________________________________________ 
 
Thank you! 
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APPENDIX B: IRB APPROVAL FORM 
IRB Approval form 
 
University of Pittsburgh 
Institutional Review Board 
3500 Fifth Avenue 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 (fax) 
http://www.irb.pitt.edu 
 
 
Memorandum 
    
To: Eve Kalynchuk 
From: Christopher Ryan, PhD, Vice Chair 
Date: 6/10/2014 
IRB#: PRO14050637 
Subject: Understanding Parental Opinions on Whole Exome Sequencing in the Prenatal Setting 
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The above-referenced project has been reviewed by the Institutional Review Board.  
Based on the information provided, this project meets all the necessary criteria for an exemption, 
and is hereby designated as "exempt" under section 
45 CFR 46.101(b)(2). 
 
 
 
Please note the following information: 
• Investigators should consult with the IRB whenever questions arise about whether 
planned changes to an exempt study might alter the exempt status. Use the "Send 
Comments to IRB Staff" link displayed on study workspace to request a review to 
ensure it continues to meet the exempt category.  
• It is important to close your study when finished by using the "Study Completed" link 
displayed on the study workspace. 
• Exempt studies will be archived after 3 years unless you choose to extend the study. If 
your study is archived, you can continue conducting research activities as the IRB has 
made the determination that your project met one of the required exempt categories. The 
only caveat is that no changes can be made to the application. If a change is needed, you 
will need to submit a NEW Exempt application. 
Please be advised that your research study may be audited periodically by the University of 
Pittsburgh Research Conduct and Compliance Office. 
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